Drug Profile
Cyclobenzaprine/etodolac - Apsen Farmaceutica
Alternative Names: Etodolac/cyclobenzaprine - Apsen FarmaceuticaLatest Information Update: 22 Feb 2023
Price :
$50
*
At a glance
- Originator Apsen Farmaceutica
- Class Amines; Analgesics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Dibenzocycloheptenes; Drug withdrawal therapies; Indoleacetic acids; Indoles; Muscle relaxants; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists; Cyclooxygenase inhibitors; Histamine H1 receptor antagonists; Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Postoperative pain
Most Recent Events
- 09 Feb 2023 Apsen Farmaceutica terminates a phase III trial in Postoperative pain (In adults, In elderly, In Volunteers, Combination therapy) in Brazil due to recruitment difficulty (NCT03127592)
- 29 Nov 2022 Cyclobenzaprine/etodolac is still in phase III trials for Postoperative pain (In volunteers) in Brazil (NCT03127592)
- 05 Oct 2020 Phase-III clinical trials in Postoperative pain (In volunteers) in Brazil (unspecified route) (NCT03127592)